Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX-0593 in ALK/ROS1-positive NSCLC after crizotinib or standard therapy failure
CTR20190789Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iruplinalkib in ALK-positive non-small cell lung cancer, non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Apr 2019; status: completed.
02
Drugs
iruplinalkib
03
Conditions
ALK-positive non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190789.